COPD-Disease Insights and Market Forecasts to 2024

“COPD: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of COPD disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for COPD, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024.

Geographies covered:

US

Germany

France

Italy

Spain

UK

Japan

Australia

Canada

Disease Indication Overview:

This section of the report gives the overview of COPD disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and details the types of COPD disease. Further details on the profile of COPD patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for COPD disease.

 Epidemiology Forecasts to 2024:

This section of the report provides the overview of COPD diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2015 till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

 Drugs Overview and Attribute Analysis:

This part of the report highlights the importance of factors influencing the physician prescription decisions in COPD disease including efficacy factors, Tolerability factors, Monitoring requirements and pricing factors.

The report further details the drugs prescribed or expected to be prescribed in COPD disease by the physicians in terms of details about the formulation, molecule, mode of administration and mechanism of action of the drugs, their patent and trial details and the expected impact of drug in the COPD market.

The report further conducts a detailed drug attribute analysis of the drugs currently prescribed or expected to be prescribed in the disease on the parameters of Efficacy, Safety and Tolerability, Convenience of Monitoring and Dosing and Drug’s coverage of the target patient pool.

 Drugs and Market Forecast to 2024:

The report in its last section provides sales and patient numbers forecast for the overall COPD market and drug wise forecasts from 2015 till 2024 at Global level and in the US, EU5, Australia and Canada markets. The forecasts are developed based on the detailed drug attribute analysis, conducted by Pharmascroll, as shared in the previous section. It is important to note that the Forecasts conducted by Pharmascroll are not based on simple projections, and are developed meticulously based on a complex forecasting model, owned by Pharmascroll, using multiple assumptions related to launch dates of the products in the market, price of the products, adherence and compliance rates of the products, dosages of the products etc. The forecast models are at the country level and can be developed at the regional level as well.

Why Purchase the Report:

  • Robust Market and Drug forecast available at country level
  • Forecast in terms of both $ sales and Patient Numbers
  • Current and Forecasted Drug treated and Diagnosed Prevalent Patient pool
  • Detailed Drug Attribute analysis on multiple Clinical Parameters
  • Multiple Countries coverage
  • Current Marketed and Pipeline Drugs coverage
  • Detailed Disease Insights coverage

1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Key Metrics

3 Disease Overview
3.1 Disease Definition
3.2 Disease Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.2.3 Impact on Quality of Life
3.3 Symptoms of the Disease
3.4 Disease Diagnosis
3.5 Treatment Guidelines
3.6 Key unmet needs

4 Disease Epidemiology
4.1 Patient Number projections by Country
4.1.1 France
4.1.2 Germany
4.1.3 Italy
4.1.4 Spain
4.1.5 United Kingdom
4.1.6 United States
4.1.7 Japan

5 Physian’s Insights
5.1 Factors impacting a physician’s prescription decision:
5.1.1 Efficacy
5.1.2 Safety
5.1.3 Monitoring requirements
5.1.4 Pricing and Reimbursement

6 Competitive Assessment and Attribute Analysis – Key Therapies
6.1 Spiriva
6.1.1 Overview
6.1.2 Patent Information
6.1.3 Clinical Status and Trial Details
6.1.4 Attribute Analysis
6.1.5 Impact of Drug on the market
6.2 Tudorza Pressair
6.2.1 Overview
6.2.2 Patent Information
6.2.3 Clinical Status and Trial Details
6.2.4 Attribute Analysis
6.2.5 Impact of Drug on the market
6.3 Seebri Neohaler
6.3.1 Overview
6.3.2 Patent Information
6.3.3 Clinical Status and Trial Details
6.3.4 Attribute Analysis
6.3.5 Impact of Drug on the market
6.4 Incruse Ellipta
6.4.1 Overview
6.4.2 Patent Information
6.4.3 Clinical Status and Trial Details
6.4.4 Attribute Analysis
6.4.5 Impact of Drug on the market
6.5 Onbrez
6.5.1 Overview
6.5.2 Patent Information
6.5.3 Clinical Status and Trial Details
6.5.4 Attribute Analysis
6.5.5 Impact of Drug on the market
6.6 Striverdi Respimat
6.6.1 Overview
6.6.2 Patent Information
6.6.3 Clinical Status and Trial Details
6.6.4 Attribute Analysis
6.6.5 Impact of Drug on the market
6.7 Advair/Seretide
6.7.1 Overview
6.7.2 Patent Information
6.7.3 Clinical Status and Trial Details
6.7.4 Attribute Analysis
6.7.5 Impact of Drug on the market
6.8 Symbicort Turbuhaler
6.8.1 Overview
6.8.2 Patent Information
6.8.3 Clinical Status and Trial Details
6.8.4 Attribute Analysis
6.8.5 Impact of Drug on the market
6.9 Breo Ellipta
6.9.1 Overview
6.9.2 Patent Information
6.9.3 Clinical Status and Trial Details
6.9.4 Attribute Analysis
6.9.5 Impact of Drug on the market
6.10 Ultibro/Utibron
6.10.1 Overview
6.10.2 Patent Information
6.10.3 Clinical Status and Trial Details
6.10.4 Attribute Analysis
6.10.5 Impact of Drug on the market
6.11 Anoro Ellipta
6.11.1 Overview
6.11.2 Patent Information
6.11.3 Clinical Status and Trial Details
6.11.4 Attribute Analysis
6.11.5 Impact of Drug on the market
6.12 Brimica Genuair/Duaklir
6.12.1 Overview
6.12.2 Patent Information
6.12.3 Clinical Status and Trial Details
6.12.4 Attribute Analysis
6.12.5 Impact of Drug on the market
6.13 Stiolto Respimat
6.13.1 Overview
6.13.2 Patent Information
6.13.3 Clinical Status and Trial Details
6.13.4 Attribute Analysis
6.13.5 Impact of Drug on the market
6.14 Daliresp/Daxas
6.14.1 Overview
6.14.2 Patent Information
6.14.3 Clinical Status and Trial Details
6.14.4 Attribute Analysis
6.14.5 Impact of Drug on the market
6.15 Trelegy Ellipta
6.15.1 Overview
6.15.2 Patent Information
6.15.3 Clinical Status and Trial Details
6.15.4 Attribute Analysis
6.15.5 Impact of Drug on the market
6.16 Trimbow
6.16.1 Overview
6.16.2 Patent Information
6.16.3 Clinical Status and Trial Details
6.16.4 Attribute Analysis
6.16.5 Impact of Drug on the market
6.17 Arnuity Ellipta
6.17.1 Overview
6.17.2 Patent Information
6.17.3 Clinical Status and Trial Details
6.17.4 Attribute Analysis
6.17.5 Impact of Drug on the market
6.18 Bevespi Aerosphere
6.18.1 Overview
6.18.2 Patent Information
6.18.3 Clinical Status and Trial Details
6.18.4 Attribute Analysis
6.18.5 Impact of Drug on the market
6.19 Lonhala Magnair
6.19.1 Overview
6.19.2 Patent Information
6.19.3 Clinical Status and Trial Details
6.19.4 Attribute Analysis
6.19.5 Impact of Drug on the market
6.20 Revefenacin
6.20.1 Overview
6.20.2 Patent Information
6.20.3 Clinical Status and Trial Details
6.20.4 Attribute Analysis
6.20.5 Impact of Drug on the market
6.21 PT010
6.21.1 Overview
6.21.2 Patent Information
6.21.3 Clinical Status and Trial Details
6.21.4 Attribute Analysis
6.21.5 Impact of Drug on the market
6.22 Nucala
6.22.1 Overview
6.22.2 Patent Information
6.22.3 Clinical Status and Trial Details
6.22.4 Attribute Analysis
6.22.5 Impact of Drug on the market
6.23 RPL554
6.23.1 Overview
6.23.2 Patent Information
6.23.3 Clinical Status and Trial Details
6.23.4 Attribute Analysis
6.23.5 Impact of Drug on the market
6.24 Fasenra
6.24.1 Overview
6.24.2 Patent Information
6.24.3 Clinical Status and Trial Details
6.24.4 Attribute Analysis
6.24.5 Impact of Drug on the market

7 Pipeline Assessment
7.1 Overview
7.2 Strategic Review of the Pipeline
7.3 Pipeline analysis by Phases of Development
7.3.1 NDA/BLA Filed
7.3.2 Phase III Pipeline
7.3.3 Phase II Pipeline
7.3.4 Phase I Pipeline
7.3.5 Preclinical Pipeline
7.3.6 Discovery Pipeline
7.4 Pipeline Analysis by Mechanism of Action
7.5 Pipeline Analysis by Novelty of Mechanism of Action
7.6 Suspended and Terminated products

8 Market Outlook
8.1 Major Markets Overview
8.1.1 Sales Forecast (2018-2024)
8.1.1 Patient Forecast (2018-2024)
8.2 Analysis by Country (Sales and Patients forecast 2018-2024)
8.2.1 France
8.2.2 Germany
8.2.3 Italy
8.2.4 Spain
8.2.5 United Kingdom
8.2.6 United States
8.2.7 Japan
8.3 Key events
8.4 Key Growth Drivers and Barriers

9 Sales and Patient Forecast for Key Drugs (Forecasts till 2024)
9.1 Spiriva
9.1.1 Value sales in USD for COPD Disease
9.1.2 Value sales by key Geographies in USD
9.1.3 Absolute Patient Numbers in COPD Disease
9.1.4 Patient Numbers by key Geographies
9.2 Tudorza Pressair
9.2.1 Value sales in USD for COPD Disease
9.2.2 Value sales by key Geographies in USD
9.2.3 Absolute Patient Numbers in COPD Disease
9.2.4 Patient Numbers by key Geographies
9.3 Seebri Neohaler
9.3.1 Value sales in USD for COPD Disease
9.3.2 Value sales by key Geographies in USD
9.3.3 Absolute Patient Numbers in COPD Disease
9.3.4 Patient Numbers by key Geographies
9.4 Incruse Ellipta
9.4.1 Value sales in USD for COPD Disease
9.4.2 Value sales by key Geographies in USD
9.4.3 Absolute Patient Numbers in COPD Disease
9.4.4 Patient Numbers by key Geographies
9.5 Onbrez
9.5.1 Value sales in USD for COPD Disease
9.5.2 Value sales by key Geographies in USD
9.5.3 Absolute Patient Numbers in COPD Disease
9.5.4 Patient Numbers by key Geographies
9.6 Striverdi Respimat
9.6.1 Value sales in USD for COPD Disease
9.6.2 Value sales by key Geographies in USD
9.6.3 Absolute Patient Numbers in COPD Disease
9.6.4 Patient Numbers by key Geographies
9.7 Advair/Seretide
9.7.1 Value sales in USD for COPD Disease
9.7.2 Value sales by key Geographies in USD
9.7.3 Absolute Patient Numbers in COPD Disease
9.7.4 Patient Numbers by key Geographies
9.8 Symbicort Turbuhaler
9.8.1 Value sales in USD for COPD Disease
9.8.2 Value sales by key Geographies in USD
9.8.3 Absolute Patient Numbers in COPD Disease
9.8.4 Patient Numbers by key Geographies
9.9 Breo Ellipta
9.9.1 Value sales in USD for COPD Disease
9.9.2 Value sales by key Geographies in USD
9.9.3 Absolute Patient Numbers in COPD Disease
9.9.4 Patient Numbers by key Geographies
9.10 Ultibro/Utibron
9.10.1 Value sales in USD for COPD Disease
9.10.2 Value sales by key Geographies in USD
9.10.3 Absolute Patient Numbers in COPD Disease
9.10.4 Patient Numbers by key Geographies
9.11 Anoro Ellipta
9.11.1 Value sales in USD for COPD Disease
9.11.2 Value sales by key Geographies in USD
9.11.3 Absolute Patient Numbers in COPD Disease
9.11.4 Patient Numbers by key Geographies
9.12 Brimica Genuair/Duaklir
9.12.1 Value sales in USD for COPD Disease
9.12.2 Value sales by key Geographies in USD
9.12.3 Absolute Patient Numbers in COPD Disease
9.12.4 Patient Numbers by key Geographies
9.13 Stiolto Respimat
9.13.1 Value sales in USD for COPD Disease
9.13.2 Value sales by key Geographies in USD
9.13.3 Absolute Patient Numbers in COPD Disease
9.13.4 Patient Numbers by key Geographies
9.14 Daliresp/Daxas
9.14.1 Value sales in USD for COPD Disease
9.14.2 Value sales by key Geographies in USD
9.14.3 Absolute Patient Numbers in COPD Disease
9.14.4 Patient Numbers by key Geographies
9.15 Trelegy Ellipta
9.15.1 Value sales in USD for COPD Disease
9.15.2 Value sales by key Geographies in USD
9.15.3 Absolute Patient Numbers in COPD Disease
9.15.4 Patient Numbers by key Geographies
9.16 Trimbow
9.16.1 Value sales in USD for COPD Disease
9.16.2 Value sales by key Geographies in USD
9.16.3 Absolute Patient Numbers in COPD Disease
9.16.4 Patient Numbers by key Geographies
9.17 Arnuity Ellipta
9.17.1 Value sales in USD for COPD Disease
9.17.2 Value sales by key Geographies in USD
9.17.3 Absolute Patient Numbers in COPD Disease
9.17.4 Patient Numbers by key Geographies
9.18 Bevespi Aerosphere
9.18.1 Value sales in USD for COPD Disease
9.18.2 Value sales by key Geographies in USD
9.18.3 Absolute Patient Numbers in COPD Disease
9.18.4 Patient Numbers by key Geographies
9.19 Lonhala Magnair
9.19.1 Value sales in USD for COPD Disease
9.19.2 Value sales by key Geographies in USD
9.19.3 Absolute Patient Numbers in COPD Disease
9.19.4 Patient Numbers by key Geographies
9.20 Revefenacin
9.20.1 Value sales in USD for COPD Disease
9.20.2 Value sales by key Geographies in USD
9.20.3 Absolute Patient Numbers in COPD Disease
9.20.4 Patient Numbers by key Geographies
9.21 PT010
9.21.1 Value sales in USD for COPD Disease
9.21.2 Value sales by key Geographies in USD
9.21.3 Absolute Patient Numbers in COPD Disease
9.21.4 Patient Numbers by key Geographies
9.22 Nucala
9.22.1 Value sales in USD for COPD Disease
9.22.2 Value sales by key Geographies in USD
9.22.3 Absolute Patient Numbers in COPD Disease
9.22.4 Patient Numbers by key Geographies
9.23 RPL554
9.23.1 Value sales in USD for COPD Disease
9.23.2 Value sales by key Geographies in USD
9.23.3 Absolute Patient Numbers in COPD Disease
9.23.4 Patient Numbers by key Geographies
9.24 Fasenra
9.24.1 Value sales in USD for COPD Disease
9.24.2 Value sales by key Geographies in USD
9.24.3 Absolute Patient Numbers in COPD Disease
9.24.4 Patient Numbers by key Geographies

10 Appendix
10.1 Bibliography
10.2 Abbreviations
10.3 Coverage
10.4 Methodology and Research conducted
10.5 Market Forecast
10.6 About Pharmascroll
10.7 Contact Us
10.8 Disclaimer

Drugs covered
Spiriva
Tudorza Pressair
Seebri Neohaler
Incruse Ellipta
Arcapta Neohaler/Onbrez
Striverdi Respimat
Advair/Seretide
Symbicort Turbuhaler
Breo Ellipta
Ultibro/Utibron
Anoro Ellipta
Brimica Genuair/Duaklir
Stiolto Respimat
Daliresp/Daxas
Trelegy Ellipta
Trimbow
Arnuity Ellipta
Bevespi Aerosphere
Lonhala Magnair
Revefenacin
PT010
Nucala
RPL554
Fasenra

Companies Covered
Boehringer Ingelheim
Pfizer
Forest Laboratories
Mylan
AstraZeneca
Menarini
Allergan
Almirall
Meda
Kyorin Holdings
Daewoong Pharmaceutical
Circassia
Eisai
Novartis
Sumitomo Dainippon Pharma
Meiji Holdings
Sosei
Vectura
SkyePharma
GlaxoSmithKline
Chiesi
Pierre Fabre
Laboratorios Farmacéuticos ROVI
Handok
Grupo Ferrer
Mitsubishi Tanabe Pharma
Endo International
Aspen Pharmacare
Faes Farma
Dong-A ST
Dong-A Socio Holdings
Hanmi Pharmaceutical
Abdi Ibrahim
Merck & Co
Astellas Pharma
Esteve
Elan
Innoviva
Cipla
Takeda
Nycomed
Theravance Biopharma
Pearl Therapeutics
PARI Medical Holding
Elevation Pharmaceuticals
PDL BioPharma
Vernalis
Verona Pharma
Kyowa Hakko Kirin
MedImmune
Lonza

Single User License Cost: $5000 Buy
Multiple User License Cost: $10000 Buy
Submit your Query
Download Table of Contents